5,5,7,7-Tetramethylcyclopenta[b]pyrazine-2-carboxylic acid | 187401-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5,5,7,7-Tetramethylcyclopenta[b]pyrazine-2-carboxylic acid
• 英文别名: 5,5,7,7-tetramethyl-6H-cyclopenta[b]pyrazine-3-carboxylic acid
• CAS: 187401-73-6
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.271
• InChiKey: XDCGBBSOIHQNNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5,5,7,7-Tetramethylcyclopenta[b]pyrazine-2-carboxylic acid 在 potassium tert-butylate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 2-chloro-4-[(5,5,7,7-tetramethyl-6H-cyclopenta[b]pyrazine-3-carbonyl)amino]benzoic acid
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 2-Pyrazinylcarboxamido- benzoates and β-Ionylideneacetamidobenzoates with Retinoidal Activity

  摘要：

  The structure-activity relationships of two series of novel retinoids (2-pyrazinylcarboxamidobenzoates and beta-ionylideneacetamidobenzoates) have been investigated by evaluating their ability to induce differentiation in both human promyelocytic leukemia (HL60) cells and mouse embryonal carcinoma (P19) cells. The most active compound (ED50 = 8.3 x 10(-9) M) of the 2-pyrazinylcarboxamidobenzoates is 4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethylquinoxalyl)-carboxamido]benzoic acid (9u), while the most active analogue of the beta-ionylideneacetamidobenzoates is 4-[3-methyl-5-(2',6',6'-trimethyl-1'-cyclohexen-1'-yl)-(2E,4E)-pentadienamido]benzoic acid (10a, ED50 = 3.2 x 10(-8) M). Our studies identify an absolute requirement for the carboxylic acid moiety on the aromatic ring to be para relative to the amide linkage for activity. Benzoate substitutions in the ortho position relative to the terminal carboxylate (9d,k,r) are well-tolerated; however, a methoxy substituent meta relative to the terminal carboxylate gives rise to only weakly active analogues (9x). Conformational studies (NMR, X-ray crystallography) of the 2-pyrazinylcarboxamidobenzoates indicate that the preferred conformation exhibits a trans-amide bond and an internal hydrogen bond between the quinoxaline N1 and HN amide which locks the torsional angle between C2 and CO in the s-trans conformation. N-Methylation (9y) results in loss of activity. Studies indicate that there is now a cis-amide bond present which redirects the carboxylate toward the pharmacophoric gem-dimethyl groups. The distance between the gem-dimethyl group and the terminal carboxylate appears to be too short to activate the retinoid receptor. N-Methylation in the beta-ionylideneacetamidobenzoate series (10c) also results in the formation of a cis-amide bond and loss of activity.

  DOI：

  10.1021/jm9801354
• 作为产物：
  描述：

  5,5,7,7-Tetramethyl-6,7-dihydro-5H-cyclopentapyrazine-2-carboxylic acid methyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 5,5,7,7-Tetramethylcyclopenta[b]pyrazine-2-carboxylic acid
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 2-Pyrazinylcarboxamido- benzoates and β-Ionylideneacetamidobenzoates with Retinoidal Activity

  摘要：

  The structure-activity relationships of two series of novel retinoids (2-pyrazinylcarboxamidobenzoates and beta-ionylideneacetamidobenzoates) have been investigated by evaluating their ability to induce differentiation in both human promyelocytic leukemia (HL60) cells and mouse embryonal carcinoma (P19) cells. The most active compound (ED50 = 8.3 x 10(-9) M) of the 2-pyrazinylcarboxamidobenzoates is 4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethylquinoxalyl)-carboxamido]benzoic acid (9u), while the most active analogue of the beta-ionylideneacetamidobenzoates is 4-[3-methyl-5-(2',6',6'-trimethyl-1'-cyclohexen-1'-yl)-(2E,4E)-pentadienamido]benzoic acid (10a, ED50 = 3.2 x 10(-8) M). Our studies identify an absolute requirement for the carboxylic acid moiety on the aromatic ring to be para relative to the amide linkage for activity. Benzoate substitutions in the ortho position relative to the terminal carboxylate (9d,k,r) are well-tolerated; however, a methoxy substituent meta relative to the terminal carboxylate gives rise to only weakly active analogues (9x). Conformational studies (NMR, X-ray crystallography) of the 2-pyrazinylcarboxamidobenzoates indicate that the preferred conformation exhibits a trans-amide bond and an internal hydrogen bond between the quinoxaline N1 and HN amide which locks the torsional angle between C2 and CO in the s-trans conformation. N-Methylation (9y) results in loss of activity. Studies indicate that there is now a cis-amide bond present which redirects the carboxylate toward the pharmacophoric gem-dimethyl groups. The distance between the gem-dimethyl group and the terminal carboxylate appears to be too short to activate the retinoid receptor. N-Methylation in the beta-ionylideneacetamidobenzoate series (10c) also results in the formation of a cis-amide bond and loss of activity.

  DOI：

  10.1021/jm9801354

文献信息

• Heterocycle-containing carboxylic acid derivative and drug containing the same
  申请人：Eisai Co. Ltd.

  公开号：US20020032202A1

  公开（公告）日：2002-03-14

  Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): 1 wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a —CONH— group or a group represented by the formula —CR 6 ═CR 7 — in which R 6 and R 7 represents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.

  描述了一种含有杂环的羧酸衍生物，其化学式如下（I）：1其中A代表含有至少一个氮原子和可能具有取代基的杂芳基团，B代表例如杂芳烷基团，—CONH—基团或由公式—CR6═CR7—所表示的基团，其中R6和R7代表H、低碳基团或类似物，D代表芳基团、杂芳基团或类似物，n1代表0或1，M代表例如羟基或低碳氧基团；或其生理上可接受的盐。作为替代视黄酸的视黄酸相关化合物，它可以提供预防和/或治疗各种疾病的方法。
• Heterocycl-containing carboxylic acid derivative and drug containing the same
  申请人：Eisai Co. Ltd.

  公开号：US20020103234A1

  公开（公告）日：2002-08-01

  Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): 1 wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a —CONH— group or a group represented by the formula —CR 6 ═CR 7 — in which R 6 and R 7 represents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.

  描述了一种含杂环的羧酸衍生物，其化学式为（I）：1，其中A代表例如至少含有一个氮原子并且可能具有取代基的杂芳基团，B代表例如杂芳烃基团，-CONH-基团或由式子-CR6═CR7-表示的基团，其中R6和R7代表H、低碳基或类似物，D代表芳烃基团、杂芳烃基团或类似物，n1代表0或1，M代表例如羟基或低碳氧基基团；或其生理上可接受的盐。作为替代视黄酸的视黄酸相关化合物，它可以提供预防和/或治疗各种疾病的方法。
• HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：Eisai Co., Ltd.

  公开号：EP0838453A1

  公开（公告）日：1998-04-29

  Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a -CONH- group or a group represented by the formula -CR6=CR7- in which R6 and R7 represents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.

  所述的是由下式(I)代表的含杂环的羧酸衍生物： 其中 A 代表例如含有至少一个氮原子并可具有取代基的杂芳基，B 代表例如杂芳基、-CONH- 基团或由式 -CR6=CR7- 代表的基团，其中 R6 和 R7 代表 H、低级烷基或类似基团，D 代表芳基、杂芳基或类似基团，n1 代表 0 或 1，M 代表例如羟基或低级烷氧基；或其生理学上可接受的盐。作为替代维甲酸的维甲酸相关化合物，它可以预防和/或治疗各种疾病。
• US5977108A
  申请人：——

  公开号：US5977108A

  公开（公告）日：1999-11-02
• US6329402B1
  申请人：——

  公开号：US6329402B1

  公开（公告）日：2001-12-11